Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised
Who needs them
Hes a former NCAA Division I wrestler and a self-described meathead in the gym, but with a focus on health. He cautions: I would never personally take or suggest anyone take any of these peptides without clear clinical evidence for benefit in treating a disease, he says
2023 ASCO Annual Meeting 41(16), 2023
At these levels, tirzepatide still activates both GLP-1 and GIP receptors, but the activation is gentler, more gradual, and far less likely to trigger the gastrointestinal side effects that make the first few weeks of standard dosing so difficult for many people
Reported side effects are mild and infrequent: transient nasal irritation, occasional headache, and rare reports of mild irritability or sleep disturbance